Evidence map›Paper›PMID 35725740›Full record

ArticleScientific reports2022

Author Correction: PR-LncRNA signature regulates glioma cell activity through expression of SOX factors.

Sergio Torres-Bayona, Paula Aldaz, Jaione Auzmendi-Iriarte, Ander Saenz-Antoñanzas, Idoia Garcia, Mariano Arrazola, Daniela Gerovska, Jose Undabeitia, Arrate Querejeta, Larraitz Egaña and 8 more

Abstract readPublished Erratum
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Sergio Torres-BayonaDonostia University Hospital, San Sebastian, Spain.
Paula AldazCellular Oncology Group, Biodonostia Institute, San Sebastian, Spain.
Jaione Auzmendi-IriarteCellular Oncology Group, Biodonostia Institute, San Sebastian, Spain.
Ander Saenz-AntoñanzasCellular Oncology Group, Biodonostia Institute, San Sebastian, Spain.
Idoia GarciaCellular Oncology Group, Biodonostia Institute, San Sebastian, Spain.
Mariano ArrazolaDonostia University Hospital, San Sebastian, Spain.
Daniela GerovskaComputational Biology and Systems Biomedicine Group and Computational Biomedicine Data Analysis Platform, Biodonostia Institute, San Sebastian, Spain.
Jose UndabeitiaDonostia University Hospital, San Sebastian, Spain.
Arrate QuerejetaDonostia University Hospital, San Sebastian, Spain.
Larraitz EgañaDonostia University Hospital, San Sebastian, Spain.
Jorge VillanúaDonostia University Hospital, San Sebastian, Spain.
Irune RuizCIBERFES, Madrid, Spain.
Cristina SarasquetaDonostia University Hospital, San Sebastian, Spain.
Enrique UrculoDonostia University Hospital, San Sebastian, Spain.
Marcos J Araúzo-BravoIKERBASQUE, Basque Foundation for Science, Bilbao, Spain.ORCID http://orcid.org/0000-0002-3264-464X
Maite HuarteCenter for Applied Medical Research, University of Navarra, Pamplona, Spain.
Nicolas SamprónCIBERFES, Madrid, Spain.
Ander MatheuCellular Oncology Group, Biodonostia Institute, San Sebastian, Spain. ander.matheu@biodonostia.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35725740
PMCPMC9209411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.